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ARTICLE
Anticonvulsant effect of minocycline on pentylenetetrazole-
induced seizure in mice: involvement of nitric oxide and
N-methyl-D-aspartate receptor
Hossein Amini-Khoei, Nastaran Kordjazy, Arvin Haj-Mirzaian, Shayan Amiri, Arya Haj-Mirzaian,
Armin Shirzadian, Amin Hasanvand, Shima Balali-Dehkordi, Mahsa Hassanipour, and Ahmad Reza Dehpour
Abstract:Anticonvulsant effects ofminocyclinehave been explored recently. This studywas designed to examine the anticonvulsant
effect of acute administration of minocycline on pentylenetetrazole-induced seizures in mouse considering the possible role of the
nitric oxide/N-methyl-D-aspartate (NMDA) pathway.We induced seizure using intravenous administration of pentylenetetrazole. Our
results showed that acute administration of minocycline increased the seizure threshold. Furthermore, co-administration of subef-
fective doses of the nonselective nitric oxide synthase (NOS) inhibitor NG-L-arginine methyl ester (10 mg/kg) and the neuronal NOS
inhibitor 7-nitroindazole (40 mg/kg) enhanced the anticonvulsant effect of subeffective doses of minocycline (40 mg/kg). We found
that inducible NOS inhibitor aminoguanidine (100mg/kg) had no effect on the antiseizure effect ofminocycline.Moreover, L-arginine
(60 mg/kg), as a NOS substrate, reduced the anticonvulsant effect of minocycline. We also demonstrated that pretreatment with the
NMDA receptor antagonists ketamine (0.5mg/kg) andMK-801 (0.05mg/kg) increased the anticonvulsant effect of subeffective doses of
minocycline. Results showed thatminocycline signiﬁcantly decreased the hippocampal nitrite level. Furthermore, co-administration
of a neuronal NOS inhibitor like NMDA receptor antagonists augmented the effect of minocycline on the hippocampal nitrite level.
In conclusion, we revealed that anticonvulsant effect of minocycline might be, at least in part, due to a decline in constitutive
hippocampal nitric oxide activity as well as inhibition of NMDA receptors.
Key words: minocycline, anticonvulsant, nitric oxide, NO, neuronal nitric oxide synthase, nNOS, N-methyl-D-aspartate, NMDA.
Résumé : On a récemment exploré les effets anticonvulsivants de la minocycline. Cette étude a été conçue en vue d’examiner
l’effet anticonvulsivant de l’administration aiguë deminocycline sur des convulsions provoquées par le pentylènetétrazole chez
la souris, en tenant compte du rôle éventuel de la voie de signalisation oxyde nitrique/N-méthyl-D-aspartate (NMDA). Nous avons
provoqué des convulsions par l’administration intraveineuse de pentylènetétrazole. Nos résultats ont montré que l’administration
aiguë de minocycline augmentait le seuil des convulsions. En outre, l’administration concomitante de doses sous-efﬁcaces de « NG-L-
argininemethyl ester » (inhibiteurnon sélectif de l’oxydenitrique synthase (NOS); 10mg/kg) et de 7-nitroindazole (inhibiteurde laNOS
neuronale; 40mg/kg) entraînait une augmentation de l’effet anticonvulsivant de doses sous efﬁcaces deminocycline (40mg/kg). Nous
avons observé que l’aminoguanidine (inhibiteur de la NOS inductible; 100 mg/kg) n’avait aucun effet sur les effets anticonvulsivants
de laminocycline. De surcroît, la L-arginine (60mg/kg), en tant que substrat de la NOS, entraînait une réduction de l’effet anticonvul-
sivant de la minocycline. Nous avons aussi montré que l’administration préalable d’antagonistes des récepteurs du NMDA, de
kétamine (0,5 mg/kg) et de MK-801 (0,05 mg/kg), entraînait une augmentation de l’effet anticonvulsivant de doses sous-efﬁcaces de
minocycline. Les résultats ont montré que la minocycline entraînait une diminution marquée des concentrations de nitrite dans
l’hippocampe. En outre, l’administration concomitante d’inhibiteurs de laNOSneuronale commedes antagonistes des récepteurs du
NMDA entraînait une augmentation de l’effet de laminocycline sur les taux de nitrite dans l’hippocampe. En conclusion, nous avons
révélé que l’effet anticonvulsivant de laminocycline pourrait être, aumoins en partie, causé par la diminution de l’activité de l’oxyde
nitrique constitutif dans l’hippocampe, ainsi que par l’inhibition des récepteurs du NMDA. [Traduit par la Rédaction]
Mots-clés :minocycline, anticonvulsivant, oxydenitrique,NO, oxydenitrique synthaseneuronale, nNOS,N-méthyl-D-aspartate, NMDA.
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Introduction
Epilepsy arises due to abnormal and excessive neuronal activity
of the brain and is recognized as a syndrome characterized by
additional co-occurring conditions (Fisher et al. 2014). Regardless
of the development of numerous antiepileptic drugs, new agents
with further anticonvulsant activity and fewer side effects are
interesting goals in neurology (Hitiris and Brodie 2006).
Minocycline, a second-generation tetracycline with broad-
spectrumantimicrobial properties, has perfect bioavailability and
outstanding blood–brain barrier permeability (Macdonald et al.
1973). Inhibition of oxidative stress (Morimoto et al. 2005) and
nitric oxide synthase (NOS) (Kim et al. 2004), blockade of N-methyl-
D-aspartate (NMDA) receptors (Munzar et al. 2002), and anti-
inﬂammatory (Yrjänheikki et al. 1999) properties have been
explained for neuroprotective effects of minocycline. Recently, the
anti-inﬂammatory agents and scavengers have been explored by
researchers (Jami et al. 2014, 2015). In this regard, evidence shows
that anti-inﬂammatory drugs that inhibit activation of microglia
possessed neuroprotective properties (Vezzani et al. 2011). There
are several preclinical studies reporting the protective effects of
minocycline on seizures (Wang et al. 2012; Wang et al. 2015;
Barker-Haliski et al. 2016). Besides animal studies, Nowak and
co-workers demonstrated that minocycline therapy signiﬁcantly
reduced the seizure frequency in patients (Nowak et al. 2012).
On the other hand, it is well known that the overactivation of
the glutamatergic system plays a fundamental role in epilepsy
(Urban´ska et al. 1992). The NMDA receptor activity contributes to
neuronal excitation and is linked to the pathophysiology of epi-
lepsy (Ghasemi and Dehpour 2014). It is well determined that
NMDA receptor blockers possess antiepileptic activity (Sato et al.
1988; Cotton et al. 1993; Freitas et al. 2006; Vataev et al. 2009).
Furthermore, ample evidence suggests that anticonvulsant effects
of antiepileptic drugs aremediated, in part, via blockade of NMDA
receptors (Ghasemi et al. 2010; Rahimi et al. 2014).
Nitric oxide (NO) is a neuromodulator involved in different
biological functions of the nervous system (Esplugues 2002;
Sadaghiani et al. 2011). Activation of the NMDA receptors initiates
production and release of NO in the brain (Diniz et al. 2016). It has
been shown that NO contributes to the pathophysiology of sei-
zures (Riazi et al. 2006). NOS produces NO from the precursor
L-arginine (Ostadhadi et al. 2016). It has been shown that blockade
of NOS is involved in the anticonvulsant effect of many drugs in
animal models of seizure (Bagetta et al. 2002; Riazi et al. 2006;
Bahremand et al. 2010a).
Although the contribution of NO in underlying mechanisms of
minocycline has been reported previously, there is little evidence
about the involvement of the NO pathway in the anticonvulsant
effect of minocycline in an experimental model of pentylenetetrazole
(PTZ) induced seizure. Moreover, according to the inhibitory ef-
fects of minocycline on neuroexcitation, the role of NMDA recep-
tors in the antiseizure effect of minocycline gained our interest.
Since little is known about the involvement of NMDA receptors
and NO in the protective effect of minocycline, we ﬁrstly aimed to
examine the anticonvulsant effect of acute administration of mi-
nocycline on PTZ-induced seizure. Secondly, we investigated the
possible contribution of the NO pathway and NMDA receptors in
this effect.
Materials and methods
Animals
Male NMRI mice, 20–30 g mass (Pasteur Institute of Iran, Teh-
ran, Iran), were used in this study. Animals were housed in groups
(four or ﬁve mice per cage) and kept at a temperature of 21–23 °C
under a 12 h regular light–dark cycle and access to food and water
ad lib. All experiments were carried out between 1200 and 1600.
Each experimental group included six animals in behavioral ex-
periments and four animals in biochemical tests and each mouse
was used only once.
Drugs
The following drugs were used: minocycline, PTZ, NG-L-arginine
methyl ester (L-NAME), aminoguanidine, 7-nitroindazole (7-NI),
L-arginine (L-arg), ketamine, and MK-801 (all purchased from
Sigma, St. Louis, Missouri, USA). 7-NI was dissolved in a 1% solution
of Tween 80 and all other drugs were freshly dissolved in physio-
logical saline and were prepared immediately before the ad-
ministrations. Except for PTZ, which was administered via the
intravenous route, all injections were through the intraperitoneal
(i.p.) route and with a volume of 5 mL/kg body mass.
Treatments
In the ﬁrst step, we examined the effects of different doses of
minocycline (20, 40, 80, and 120 mg/kg) on seizure threshold.
Control animals in this step received acute i.p. injections of the
appropriate vehicle (saline at 5 mL/kg). In the next step, minocy-
cline (120 mg/kg) was administered at 30, 60, and 120 min prior to
PTZ injection.
We assessed the effects of L-NAME (a nonselective NOS inhibitor,
10 mg/kg) (Amiri et al. 2016b; Haj-Mirzaian et al. 2016a), amino-
guanidine (a selective inducible NOS (iNOS) inhibitor, 100 mg/kg)
(Shafaroodi et al. 2012), 7-NI (a selective neuronal NOS (nNOS)
inhibitor, 40 mg/kg) (Yahyavi-Firouz-Abadi et al. 2006), and L-arg
(an NO precursor, 60 mg/kg) (Payandemehr et al. 2014) on the
seizure threshold in mice. L-NAME and aminoguanidine were
administered 60 min, L-arginine 45 min, and 7-NI 30 min before
administration of PTZ (Yahyavi-Firouz-Abadi et al. 2006). Further-
more, the possible involvement of the nitrergic system on the
anticonvulsant activity of minocycline was examined through
co-administrationof the subeffective doses of L-NAME (simultaneous
administration with minocycline), aminoguanidine (simultaneous
administration with minocycline), and 7-NI (30 min after minocy-
cline administration) with the subeffective dose of minocycline.
Moreover, the effective dose of minocycline was co-administered
with the effective dose of L-arg (15 min after minocycline admin-
istration). To exclude the effect of vehicle administration on be-
havioral assessments, saline or 1% solution of Tween 80 (5 mL/kg)
was injected before PTZ into the control groups.
In the next part, we examined the effects of ketamine (0.5 mg/kg)
and MK-801 (0.05 mg/kg) on the seizure threshold (Ghasemi et al.
2010; Amiri et al. 2016a). Ketamine andMK-801 were administered
60 min before PTZ injection. Furthermore, the probable involve-
ment of NMDA receptors in the anticonvulsant activity of mino-
cycline was examined through co-administration of the subeffective
doses of ketamine and MK-801 with the subeffective dose of mino-
cycline. To rule out the effect of vehicle administration on behav-
ioral assessments, saline (5 mL/kg) was injected 60min before PTZ
into the control groups. The doses and times of administrations
were chosen based on our pilot study and also on previously pub-
lished studies (Homayoun et al. 2002b; Yahyavi-Firouz-Abadi et al.
2006; Ghasemi et al. 2010; Rahimi et al. 2014; Amiri et al. 2016a).
Figure 1 shows the chronologic design of this study.
Further, we measured the hippocampal nitrite levels following
treatment with minocycline (40 and 120 mg/kg) and also subse-
quent co-administration of minocycline with NO/NMDA agents
(L-arg, 7-NI, and MK-801). After these treatments (60 min after
minocycline injection), animals were euthanized under anesthe-
sia using diethyl ether and hippocampi were dissected on an ice-
cold surface and immediately immersed in liquid nitrogen. Tissue
homogenates were prepared and hippocampal nitrite content
was measure using the described method.
Determination of clonic seizure threshold (CST)
To determine the CST inmice, we used the previously described
method (Amiri et al. 2014, 2016b, 2017; Amini-Khoei et al. 2015).
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Brieﬂy, a winged infusion set (30 gauge) was used to infuse the PTZ
(0.5%) at a constant rate of 1 mL/min into the tail vein of the freely
moving subject. We stopped the infusion whenever forelimb clo-
nus followed by full clonus of the body occurred (began with
running and then loss of righting ability). The minimal dose of
PTZ (milligrams per kilogram of mouse mass) needed to induce a
clonic seizure was considered as the index of seizure threshold.
Because PTZ was administrated at a constant rate (1 mL/min), du-
ration to induce seizure depended on dose and time of PTZ injec-
tion (Amiri et al. 2016a).
Nitrite assay
To determine the NO level in the hippocampus, we measured
the nitrite level as the result of the NO end product (Ding et al.
2010; Kordjazy et al. 2015; Haj-Mirzaian et al. 2016b). Nitrite level
was measured with a colorimetric assay based on the Griess reac-
tion in each hippocampus sample. Concentration of nitrite was
determined by reference to a standard curve of sodium nitrite
(Sigma) and normalized to the mass of each sample.
Ethics declarations
The protocol for this project has been approved by the ethics
committee of the Tehran University of Medical Sciences (Tehran,
Iran) and all experiments were performed according to the insti-
tutional guidelines for animal care and use. All animal manipula-
tionswere carried out according to the “Guide for the care and use
of laboratory animals (8th ed., 2011, published by the National
Academies Press, Washington, DC, USA) and legislation for the
protection of animals used for scientiﬁc purposes (Directive 2010/
63/EU).
Statistical analysis
Data were expressed as mean ± SEM of CST in each experimen-
tal group. One-way ANOVA followed by Tukey’s post hoc compar-
isonwas used to analyze the results. The GraphPad Prism software
(version 6) was used to illustrate the results. The analysis was
based on normally distributed data and a P value of less than 0.05
was considered statistically signiﬁcant. The sample size was cal-
culated by power calculations using G power software (ver.3.1.7)
Fig. 1. Chronologic study design. [Colour online.]
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(Franz Faul, Universitat Kiel, Germany). The  error was set at 0.05
and the power (1 – ) at 0.8 and the required total sample size per
group was calculated as six to eight in behavioral tests and four in
biochemical tests. Also, it should be noted that the post hoc power
analysis of all statistical reports was more than 80%.
Results
Effect of minocycline on seizure threshold
Figure 2 shows the time course of the anticonvulsant effect
of minocycline (120 mg/kg). The data showed that minocycline
exerted an anticonvulsant effect (F[3,25] = 44.04, P < 0.001) with
maximal effect at 60 min after administration (P < 0.001) in com-
parison with saline-treated animals.
Figure 3 shows the effects of acute i.p. administration of various
doses of minocycline on PTZ-induced seizure. One-way ANOVA
revealed a signiﬁcant anticonvulsant effect for minocycline
(F[4,25] = 10.12, P < 0.001) at doses of 80 mg/kg (P < 0.05) and
120 mg/kg (P < 0.001) with maximal effect at 120 mg/kg. Minocy-
cline at doses of 20 and 40 mg/kg did not produce a signiﬁcant
anticonvulsant effect when compared with the control group
(P > 0.05).
Effects of NOS inhibitors on the anticonvulsant effect of
minocycline
We examined the effect of the nonselective NOS inhibitor
L-NAME on the anticonvulsant effect of minocycline (Fig. 4A).
Analysis with one-way ANOVA revealed a signiﬁcant effect for
L-NAME (F[3,20] = 11.68, P < 0.001). Tukey’s post hoc comparison
showed that L-NAME (10 mg/kg) did not alter the CST in the con-
trol groups. Nevertheless, L-NAME (10 mg/kg) enhanced the anti-
convulsant effect induced by minocycline (40 mg/kg) compared
with the control group (P < 0.001).
Figure 4B shows the effect of 7-NI onminocycline-inducedmod-
ulation of seizure threshold. One-way ANOVA determined a sig-
niﬁcant effect for 7-NI (F[3,20] = 18.03, P < 0.001). Injection of 7-NI
alone (40 mg/kg) did not change the CST but augmented the anti-
convulsant effect of minocycline (40 mg/kg) compared with the
control group (P < 0.001).
We studied the effect of the iNOS inhibitor aminoguanidine on
the anticonvulsant effect of minocycline to test the possible in-
volvement of iNOS. Analysis with one-way ANOVA did not show a
signiﬁcant effect for aminoguanidine (F[3,20] = 2.816, P > 0.05).
Similarly, pretreatment with aminoguanidine (100 mg/kg) did not
affect the CST in either saline or minocycline-treated (40 mg/kg)
groups (P > 0.05) (Fig. 4C).
Effect of co-administration of L-arg with minocycline on
CST
One-way ANOVA analysis revealed a signiﬁcant effect for treat-
ment with the NO precursor L-arg (60mg/kg) on CST (F[3,20] = 10.42,
P < 0.001) (Fig. 5). Post- hoc test evaluation showed that L-arg alone
did not change the CST in control animals. However, L-arg in
combination with minocycline signiﬁcantly reversed the anticon-
vulsant effect of minocycline (P < 0.01 compared with the mino-
cycline group).
Effects of NMDA antagonists on the anticonvulsant effect of
minocycline
We examined the effect of NMDA antagonists on the anticon-
vulsant effect of minocycline (Fig. 6). One-way ANOVA showed a
signiﬁcant effect for ketamine (F[3,20] = 6.624, P < 0.01) (Fig. 6A) and
MK-801 (F[3,20] = 8.843, P < 0.01) (Fig. 6B). Analysis with one-way
ANOVA followed by Tukey’s post hoc test demonstrated that ket-
amine (0.5mg/kg) andMK-801 (0.05mg/kg) did not alter the CST in
the control (vehicle-received) groups, but both of them enhanced
the anticonvulsant effect of minocycline (40 mg/kg) compared
with either drug alone (P < 0.01).
Hippocampal nitrite assay
One-way ANOVA determined the signiﬁcant effects of minocy-
cline treatment on the hippocampal nitrite levels (F[2,9] = 19.60,
P < 0.001) (Fig. 7A). Tukey’s post hoc analysis revealed that mino-
cycline (120 mg/kg) (but not 40 mg/kg) induced a signiﬁcant
decline in the hippocampal nitrite levels compared with saline-
administered animals (P < 0.01).
In the next part, the possible effect of minocycline and nNOS
inhibitor/NMDA receptor antagonist co-administration on the
hippocampal nitrite level was evaluated (F[5,18] = 3.466, P < 0.05)
(Fig. 7B). Results obtained from Tukey’s post hoc test revealed that
administration of 7-NI (40 mg/kg), MK-801 (0.05 mg/kg), and mino-
cycline (40 mg/kg) alone failed to change the hippocampal nitrite
content; however, co-administration of a subeffective dose of 7-NI
with the subeffective dose of minocycline produced a signiﬁcant
Fig. 2. Time course effect of minocycline on pentylenetetrazole
(PTZ) induced seizure: effect of acute minocycline administration on
clonic seizure threshold (CTS) in PTZ-injected mice. Minocycline
(120 mg/kg) was injected 30, 60, and 120 min prior to PTZ injection
and the CST was evaluated. Values are expressed as the mean ± SEM
analyzed by one-way ANOVA followed by Dunnett’s multiple
comparison test (n = 6 for all groups). *P < 0.05 and ***P < 0.001
versus the control group (t = 0). PTZ was administrated at a constant
rate of 1 mL/min.
Fig. 3. Effect of different doses of minocycline on pentylenetetrazole
(PTZ) induced seizure: effect of acute administration of minocycline
(20, 40, 80, and 120 mg/kg i.p. 60 min before PTZ injection) on the
clonic seizure threshold in PTZ-induced seizures in mice. Values are
expressed as the mean ± SEM analyzed by one-way ANOVA followed
by Dunnett’s multiple comparison test (n = 6 for all groups).
**P < 0.01 and ***P < 0.001 versus the control (saline-injected) group.
PTZ was administrated at a constant rate of 1 mL/min.
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decrease in hippocampal nitrite levels in comparison with the
animals receiving saline/Tween80 (P < 0.05) (Fig. 7B). Also, co-
administration of MK-801 with minocycline caused a signiﬁcant
decrease in hippocampal nitrite levels in comparison with the
saline/Tween80-treated group (P < 0.05) (Fig. 7B).
Furthermore, we determined the effects of L-arg (60 mg/kg) as
well as co-administration of an effective dose of minocycline
(120 mg/kg) with L-arg (60 mg/kg) on the hippocampal nitrite level
(F[3,12] = 72.17, P < 0.001) (Fig. 8). Results showed that minocycline
(120 mg/kg) signiﬁcantly decreased the nitrite level in the hip-
pocampus in comparison with the vehicle-received group (P < 0.01).
Moreover, co-administration of L-arg (60 mg/kg) signiﬁcantly re-
versed the effect of the effective dose of minocycline (P < 0.01).
Discussion
The results of the present study showed that acute administra-
tion of minocycline exerted an anticonvulsant effect in the PTZ
model of seizure. In addition, administration of subeffective doses
of the NOS inhibitor L-NAME, the consecutive NOS inhibitor 7-NI,
and NMDA antagonists potentiated the anticonvulsant effect of a
subeffective dose of minocycline. Furthermore, we found that the
iNOS inhibitor aminoguanidine, did not affect the effect of mino-
cycline. The L-arg NO precursor diminished the beneﬁcial effect
of minocycline. Moreover, our results demonstrated that co-
administration of subeffective doses of NMDA receptor antago-
nists and NOS inhibitors (L-NAME and 7-NI) with a subeffective
dose of minocycline signiﬁcantly decreased the hippocampal ni-
trite level.
The augmented seizure threshold subsequent to minocycline
treatment is consistent with previous studies describing anticon-
vulsant properties for minocycline (Wang et al. 2012; Ahmadirad
et al. 2014). There is little information on the role of NO andNMDA
receptors in the protective effects ofminocycline in seizures, so in
the present study, we aimed to investigate this interesting rela-
tionship.
Wang and colleagues showed the dose-dependent anticonvul-
sant activity for minocycline against partial seizures in a minimal
clonic seizure model (Wang et al. 2012), but they did not deter-
mine the underlying mechanisms of minocycline against seizure.
Recent experimental studies on seizure have reported that mino-
cycline inhibited neuronal death, suppressed seizure activity, and
inhibited neuroinﬂammation (Heo et al. 2006; Riazi et al. 2008);
Galic et al. 2009). Minocycline treatment in a patient with astro-
cytoma potently reduced the frequency of seizures (Nowak et al.
2012). On the contrary, other evidence showed that minocycline
could not exert anticonvulsant effects in a status epilepticus
model in rat (Russmann et al. 2016).
Although several molecular targets have been suggested, the
detailed mechanisms of anticonvulsant effects of minocycline re-
main unclear. It has been determined that minocycline potently
inhibits microglial activation and inﬂammatory reactions in the
central nervous system (Yenari et al. 2006). Given that pro- and
anti-inﬂammatory mediators are produced at the sites of seizure,
it is likely that minocycline via its anti-inﬂammatory effects ex-
erts anticonvulsant properties (Murashima et al. 2008). The short
time of peak effect indicates that minocycline might have other
immediate effects on suppressing neuronal excitability as well as
Fig. 4. Effect of pretreatment with nitric oxide synthase inhibitors on the anticonvulsant effect of minocycline: effect of administration of
(A) NG-L-arginine methyl ester (LMN) (10 mg/kg), (B) 7-nitroindazole (7-NI) (40 mg/kg), and (C) aminoguanidine (AG) (100 mg/kg) with saline or
minocycline (Mino) (40 mg/kg) on the clonic seizure threshold in pentylenetetrazole (PTZ) injected mice. Values are expressed as the mean ±
SEM analyzed by one-way ANOVA followed by Tukey’s multiple comparison test (n = 6 for all groups). ***P < 0.001 versus the vehicle-injected
group. PTZ was administrated at a constant rate of 1 mL/min.
Fig. 5. Effect of pretreatment with L-arginine on the anticonvulsant
effect of minocycline: effect of L-arginine (L-arg) administration
(60 mg/kg) with saline or minocycline (Mino) (120 mg/kg) on the
clonic seizure threshold in pentylenetetrazole (PTZ) injected mice.
Values are expressed as the mean ± SEM analyzed by one-way
ANOVA followed by Tukey’s multiple comparison test (n = 6 for all
groups). ***P < 0.001 versus vehicle (saline) injected group and
$$P < 0.01 versus the minocycline-treated group. PTZ was
administrated at a constant rate of 1 mL/min.
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anti-inﬂammatory activity (Wang et al. 2012). Considering previ-
ous studies that revealed an inhibitory effect for minocycline on
the NO pathway (Mora et al. 2014; Saeedi Saravi et al. 2016), we
assessed the effects of NOS inhibitors and the NO precursor on the
anticonvulsant activity of minocycline in the PTZ model of sei-
zure. We found that NOS inhibitors at their subeffective doses
werenotable toexert ananticonvulsant effect,while co-administration
of these agents with a subeffective dose of minocycline signiﬁ-
cantly increased the seizure threshold. Furthermore, our ﬁndings
showed that administration of L-arg reversed the anticonvulsant
effect of an effective dose of minocycline. According to deter-
mined results on co-administration of NOS inhibitors and the NO
precursor with minocycline, it can be suggested that NO may
mediate the effect of minocycline on the seizure threshold. An
interesting ﬁnding of the present study is that the iNOS inhibitor
aminoguanidine failed to change the anticonvulsant effect of mi-
nocycline, suggesting the noticeable role of nNOS in the anticon-
vulsant effect of minocycline. Although the literature evidenced
that minocycline is a blocker of iNOS expression and activity
(Sadowski and Steinmeyer 2001; Huang et al. 2009), this effect
might not contribute to the antiseizure activity of this drug in the
PTZ-induced seizures, as we conducted experiments on normal
animals without an inﬂammatory condition.
Ample studies have proposed an established role for NO in an-
tiseizure activity of antiepileptic agents (Payandemehr et al. 2014;
Shafaroodi et al. 2015). The role of NO in regulating the seizure
Fig. 6. Effect of pretreatment with N-methyl-D-aspartate antagonists on the anticonvulsant effect of minocycline: effect of administration of
(A) ketamine (Ket) (0.5 mg/kg) and (B) MK-801 (0.05 mg/kg) with saline or minocycline (Mino) (40 mg/kg) on the clonic seizure threshold in
pentylenetetrazole (PTZ) injected mice. Values are expressed as the mean ± SEM analyzed by one-way ANOVA followed by Tukey’s multiple
comparison test (n = 6 for all groups). **P < 0.001 versus the control saline (vehicle) injected group. PTZ was administrated at a constant rate of
1 mL/min.
Fig. 7. Effect of minocycline, neuronal nitric oxide synthase inhibitor, and N-methyl-D-aspartate receptor antagonist (MK-801) treatment on
the hippocampal (HIPP) nitrite level: effect of administration of (A) minocycline (Mino) 40 and 120 mg/kg (60 min before measurement) and
(B) 7-nitroindazole (7-NI) (40 mg/kg) and MK-801 (0.05 mg/kg) with Tween80/saline or Mino (40 mg/kg) on the hippocampal nitrite level in mice.
Values are expressed as the mean ± SEM analyzed by one-way ANOVA followed by Tukey’s multiple comparison test (n = 4 for all groups).
*P < 0.05 and **P < 0.01 versus the control saline or vehicle (saline and Tween80) injected group.
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threshold depends on the type of seizure, source of NO, and other
related neurotransmitters (Osonoe et al. 1994; Nidhi et al. 1999).
Results of the present study are in line with previous research
emphasizimg the role of constitutive NO inmediating the activity
of many anticonvulsants (Homayoun et al. 2002a; Gholipour et al.
2008; Bahremand et al. 2010a; Payandemehr et al. 2014). It has
been reported that NO reduced the activity of the GABAergic neu-
rons and increased the seizure susceptibility (Robello et al. 1996).
It is believed that NO could mediate the pathophysiology of sei-
zures and seems to be an end product of many excitatory path-
ways that lead to seizures (Bahremand et al. 2010b). In addition,
there is a suggested role for abnormal nNOS expression in trigger-
ing limbic seizures and delayed excitotoxic damage in the hip-
pocampus (Bagetta et al. 2002). Another study conﬁrmed that
abnormally increased nNOS activity triggers mechanisms that
evoke seizures (Rajasekaran et al. 2003). It can be suggested
that inhibition of nNOS may be associated with the protective
effect of minocycline against seizures.
Ionotropic glutamate NMDA receptors are considered as essen-
tial modulators for nNOS activity/NO release within the central
nervous system (Wu et al. 2001; Filpa et al. 2015). The results of our
experiment suggested that the anticonvulsant effect of minocy-
cline could be partially due to decrease in glutamate exocytosis.
Previous reports showed that minocycline reversed some NMDA-
induced effects (Tikka and Koistinaho 2001; Pi et al. 2004;
Garcia-Martinez et al. 2010). The neuroprotective effects and also
the central nervous system side effects of minocycline are similar
to NMDA receptor antagonists (Munzar et al. 2002). On the other
hand, minocycline is thought to inhibit NMDA receptor overex-
pression (Pu et al. 2013). Minocycline can evidently inhibit NO
production (Amin et al. 1996), which acts as an intracellular mes-
senger for NMDA glutamatergic neurotransmission (Bujas-Bobanovic
etal. 2000). Therefore, inhibition of NO synthesismight explain the
potentiation of effects of minocycline by NMDA blockers. Consid-
ering the interaction of minocycline with NMDA receptors, in the
current study, we evaluated the effect of co-administration of
subeffective doses of minocycline with NMDA receptor blockers
(ketamine and MK-801) on the PTZ model of seizure. Our ﬁndings
showed that administration of subeffective doses of NMDA antag-
onists signiﬁcantly increased the seizure threshold following
treatment of subeffective doses of minocycline. These results pro-
vide clear evidence that NMDA receptors, at least partially, medi-
ated the anticonvulsant effect of minocycline. Preclinical studies
have demonstrated that the NMDA receptors are involved inmod-
ulation of seizure susceptibility and brain excitation in seizure
(Gmiro and Serdyuk 2008; Mareš andMikulecká 2009). Our results
are in line with previous studies declaring that blockade of NMDA
receptors decreased susceptibility to seizure development (Borris
et al. 2000; Zellinger et al. 2014; Schidlitzki et al. 2017).
Our study showed that the anticonvulsant activity of minocy-
cline, at least in part, mediates through modulation of the gluta-
matergic and nitrergic pathways. Our results warrant further
experimental and clinical investigations to conﬁrm the involve-
ment of the NO/NMDA pathway in the anticonvulsant effect of
minocycline. Although the Federal Drug Administration lists con-
vulsion as a side effect forminocycline, this uncommon side effect
has been observed with speciﬁc doses used for treatment of mi-
crobial infections. In this study, we used lower doses of minocy-
cline in comparison with the usual dose used for infectious
diseases; however, further investigations are warranted in the
future to assess this consideration. Since there is a possible sex
difference in the response to neuroprotective agents, the effect of
minocycline and its mechanism of action on female mice need to
be clariﬁed in future studies. Furthermore, more research in the
future should be conducted to understand the mechanisms of
action and contribution of other pathways in the antiseizure ac-
tivity of minocycline.
Conclusions
In conclusion, our results showed that acute minocycline ad-
ministration enhanced the seizure threshold in the PTZ model of
seizure in mice. We demonstrated for the ﬁrst time that the anti-
convulsant effect of minocycline might be related to a decline in
iNOS activity and also NMDA receptor inhibition. The novelty of
the present work is that an anticonvulsant effect ofminocycline is
partly associated with its inhibitory effect on the NMDA/nNOS
pathways and reduction of NO level in the hippocampus.
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